Mark Stares

10.4k total citations · 5 hit papers
42 papers, 4.7k citations indexed

About

Mark Stares is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Mark Stares has authored 42 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in Mark Stares's work include Gut microbiota and health (13 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Inflammatory Biomarkers in Disease Prognosis (9 papers). Mark Stares is often cited by papers focused on Gut microbiota and health (13 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Inflammatory Biomarkers in Disease Prognosis (9 papers). Mark Stares collaborates with scholars based in United Kingdom, Australia and United States. Mark Stares's co-authors include Trevor D. Lawley, Nitin Kumar, Samuel C. Forster, Hilary P. Browne, David Goulding, Bridget A. Neville, Blessing O. Anonye, Julian Parkhill, Alan W. Walker and Sylvia H. Duncan and has published in prestigious journals such as Nature, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Mark Stares

38 papers receiving 4.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dominant and diet-responsive groups of bacteria within the human colonic microbiota

2010 1.2k citations Mark Stares et al. profile →
Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation

2016 797 citations Hilary P. Browne, Samuel C. Forster et al. profile →
Stunted microbiota and opportunistic pathogen colonization in caesarean-section birth

2019 671 citations Yan Shao, Samuel C. Forster et al. profile →
Targeted Restoration of the Intestinal Microbiota with a Simple, Defined Bacteriotherapy Resolves Relapsing Clostridium difficile Disease in Mice

2012 404 citations Trevor D. Lawley, Simon Clare et al. profile →
A human gut bacterial genome and culture collection for improved metagenomic analyses

2019 347 citations Samuel C. Forster, Nitin Kumar et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Stares United Kingdom	17	3.3k	1.2k	817	792	595	42	4.7k
Ilseung Cho United States	15	3.9k 1.2×	1.1k 0.9×	1.2k 1.4×	550 0.7×	628 1.1×	29	5.8k
Martin Iain Bahl Denmark	37	3.4k 1.0×	806 0.7×	1.2k 1.5×	775 1.0×	390 0.7×	91	5.1k
Stanislas Mondot France	26	2.7k 0.8×	737 0.6×	948 1.2×	611 0.8×	511 0.9×	57	4.3k
Samuel C. Forster Australia	29	3.8k 1.2×	1.1k 0.9×	571 0.7×	689 0.9×	826 1.4×	53	6.3k
Tomomi Kuwahara Japan	28	3.7k 1.1×	1.4k 1.2×	693 0.8×	935 1.2×	562 0.9×	97	6.0k
Katri Korpela Finland	33	3.3k 1.0×	1.2k 1.0×	1.1k 1.3×	543 0.7×	639 1.1×	60	5.0k
Timothy L. Tickle United States	14	3.9k 1.2×	967 0.8×	850 1.0×	610 0.8×	638 1.1×	21	5.3k
William Van Treuren United States	16	4.0k 1.2×	1.1k 1.0×	1.4k 1.7×	685 0.9×	412 0.7×	16	5.2k
Sylvie Miquel France	25	2.9k 0.9×	878 0.8×	652 0.8×	1.0k 1.3×	372 0.6×	33	3.9k
Johan Dicksved Sweden	33	3.4k 1.0×	1.3k 1.1×	613 0.8×	954 1.2×	709 1.2×	86	5.3k

Countries citing papers authored by Mark Stares

Since Specialization

Citations

This map shows the geographic impact of Mark Stares's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Stares with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Stares more than expected).

Fields of papers citing papers by Mark Stares

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Stares. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Stares. The network helps show where Mark Stares may publish in the future.

Co-authorship network of co-authors of Mark Stares

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Stares. A scholar is included among the top collaborators of Mark Stares based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Stares. Mark Stares is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brown, Leo R., Rebekah Patton, I.C. Munro, et al.. (2025). Dissecting the global leadership initiative on malnutrition criteria in advanced cancer: Reduced intake vs. inflammation. Clinical Nutrition ESPEN. 67. 114–121.

Conway, Alicia‐Marie, Matthew Robinson, Matthew J. Concannon, et al.. (2024). CUPCOMP: A multi-site UK trial in carcinoma of unknown primary: A comparison across tissue and liquid biomarkers.. Journal of Clinical Oncology. 42(16_suppl). 3059–3059. 1 indexed citations

Shao, Yan, Cristina García-Mauriño, Simon Clare, et al.. (2024). Primary succession of Bifidobacteria drives pathogen resistance in neonatal microbiota assembly. Nature Microbiology. 9(10). 2570–2582. 20 indexed citations

Phillips, I., Peter Hall, Fiona O’Brien, et al.. (2024). Early prehabilitation reduces admissions and time in hospital in patients with newly diagnosed lung cancer. BMJ Supportive & Palliative Care. 15(1). 125–129. 2 indexed citations

Stares, Mark, Robert J. Jones, Stefan N. Symeonides, et al.. (2023). Real-world survival outcomes of patients (pts) treated with 6-weekly pembrolizumab 400mg (pem6w) plus axitinib (axi) for advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology. 41(6_suppl). 645–645. 1 indexed citations

Stares, Mark, et al.. (2023). Immune-Related Adverse Events, Biomarkers of Systemic Inflammation, and Survival Outcomes in Patients Receiving Pembrolizumab for Non-Small-Cell Lung Cancer. Cancers. 15(23). 5502–5502. 9 indexed citations

Crobach, Monique J. T., Bastian Hornung, Cees M. Verduin, et al.. (2023). Screening for Clostridioides difficile colonization at admission to the hospital: a multi-centre study. Clinical Microbiology and Infection. 29(7). 891–896. 8 indexed citations

Forster, Samuel C., Junyan Liu, Nitin Kumar, et al.. (2022). Strain-level characterization of broad host range mobile genetic elements transferring antibiotic resistance from the human microbiome. Nature Communications. 13(1). 1445–1445. 108 indexed citations

Forster, Samuel C., Simon Clare, Katherine Harcourt, et al.. (2022). Identification of gut microbial species linked with disease variability in a widely used mouse model of colitis. Nature Microbiology. 7(4). 590–599. 70 indexed citations

10.

Price, Gareth, Mark Stares, Adnan Tufail, et al.. (2022). Adjuvant durvalumab post-chemoradiotherapy in stage III non-small cell lung cancer: experience from the Edinburgh Cancer Centre. Lung Cancer. 165. S34–S34.

11.

Stares, Mark, et al.. (2022). Initial active surveillance for patients with metastatic renal cell carcinoma: 10 years' experience at a regional cancer Centre. Cancer Medicine. 12(5). 5255–5264. 4 indexed citations

12.

Maclennan, Kirsty, et al.. (2021). Scottish Immunotherapy Prognostic Score: biomarker of systemic inflammation predicts response to first-line pembrolizumab for metastatic non-small cell lung cancer. Lung Cancer. 156. S43–S43. 2 indexed citations

13.

Stares, Mark, James Leach, Kirsty Maclennan, et al.. (2021). Hypoalbuminaemia as a Prognostic Biomarker of First-Line Treatment Resistance in Metastatic Non-small Cell Lung Cancer. Frontiers in Nutrition. 8. 734735–734735. 27 indexed citations

14.

Stares, Mark, Karin Purshouse, Gillian Knowles, et al.. (2021). Characterisation and outcomes of patients referred to a regional cancer of unknown primary team: a 10-year analysis. British Journal of Cancer. 125(11). 1503–1510. 7 indexed citations

15.

Vervier, Kévin, Nitin Kumar, Anne Adoum, et al.. (2021). Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet. Gut. 71(9). 1821–1830. 94 indexed citations

16.

Stares, Mark, R. A. Patton, Gillian Knowles, et al.. (2020). A biobank analysis of prognostic biomarkers of the systemic inflammatory response in patients presenting with malignancy of undefined primary origin. European Journal of Cancer. 139. 1–9. 5 indexed citations

17.

Forster, Samuel C., Nitin Kumar, Blessing O. Anonye, et al.. (2019). A human gut bacterial genome and culture collection for improved metagenomic analyses. Nature Biotechnology. 37(2). 186–192. 347 indexed citations breakdown →

18.

Stares, Mark, Samra Turajlic, Andrew J.S. Furness, et al.. (2016). ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma.. Journal of Clinical Oncology. 34(15_suppl). TPS4583–TPS4583. 5 indexed citations

19.

Soultati, Aspasia, Mark Stares, Charles Swanton, James Larkin, & Samra Turajlic. (2015). How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?. Current Opinion in Urology. 25(5). 358–366. 25 indexed citations

20.

Krishnan, Babu, et al.. (2013). PTU-094 Should Liver Biopsies be Reported by Pathologists with a Subspecialist Interest in Hepatology?. Gut. 62(Suppl 1). A83.3–A84. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact